Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics has announced a promising Q2 2024 with a strategic restructuring of a $29 million EIB loan into equity, potentially resolving its Nasdaq compliance issues by late August. The company is also confident in its CDMO business, anticipating revenue growth following targeted marketing efforts and successful biotech collaborations. Additionally, Scinai reports advancements in its NanoAb drug development, with positive regulatory feedback and preparation for a Phase 1/2a clinical trial in plaque psoriasis.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
